Abd Jalil Afdhal Afiq, Wan Muhamad Hatta Sharifah Faradila, Mohamad Aimi Fadilah, Abdul Rani Mohammed Fauzi
Department of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia.
Endocrine and Diabetes Unit, Department of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia.
Case Rep Med. 2021 Apr 19;2021:5544848. doi: 10.1155/2021/5544848. eCollection 2021.
Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed.
地诺单抗是一种与人核因子κB受体活化因子配体（RANKL）结合的人单克隆抗体。它主要用于治疗各种原因引起的骨质疏松症，特别是在对双膦酸盐难治的情况下或肾功能受损时。它也用于治疗恶性肿瘤相关的高钙血症。高钙血症有许多原因，但它很少与肉芽肿性疾病如结核性胸腔积液相关。我们报告一例由结核性胸腔积液引起的高钙血症病例，该患者最初因左侧中等量胸腔积液入院，血清校正钙水平为3.48 mmol/L。在其他干预措施失败后，皮下注射地诺单抗72小时内钙水平成功恢复正常。
